Get the Stockscreener App
26.02
4.27%
-1.16
Capricor Therapeutics Inc stock is traded at $26.02, with a volume of 1.78M.
It is down -4.27% in the last 24 hours and up +343.27% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$27.18
Open:
$26.55
24h Volume:
1.78M
Relative Volume:
0.65
Market Cap:
$1.42B
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-31.35
EPS:
-0.83
Net Cash Flow:
$-33.33M
1W Performance:
-3.24%
1M Performance:
+343.27%
6M Performance:
+86.66%
1Y Performance:
+81.45%
1-Day Range:
$25.59
$27.12
1-Week Range:
$25.59
$31.44
52-Week Range:
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
26.02 | 1.48B | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | Alliance Global Partners | Buy |
| Jun-26-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Sidley Represents Capricor Therapeutics in US$172.5 Million Common Stock Offering - Sidley Austin
Capricor: A Detailed Examination Of Hope-3 (NASDAQ:CAPR) - Seeking Alpha
Piper Sandler Reiterates Overweight Rating on CAPR, Raises Price Target | CAPR Stock News - GuruFocus
What Does the Market Think About Capricor Therapeutics Inc? - Benzinga
Biotech Stocks To Add to Your WatchlistDecember 5th - MarketBeat
A strong week for data readouts: Clinical Report - BioCentury
Capricor's cell therapy shows breakthrough results in Duchenne muscular dystrophy trial - Indian Pharma Post
Kennedy Capital Management LLC Reduces Position in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Oppenheimer Maintains Capricor Therapeutics (CAPR) Outperform Recommendation - Nasdaq
Oppenheimer raises Capricor Therapeutics price target to $54 on positive trial data - Investing.com Canada
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 5.8%What's Next? - MarketBeat
Stock Traders Purchase High Volume of Call Options on Capricor Therapeutics (NASDAQ:CAPR) - MarketBeat
Oppenheimer Raises Capricor Therapeutics (CAPR) Price Target to $54 | CAPR Stock News - GuruFocus
Oppenheimer Adjusts Capricor Therapeutics PT to $54 From $22, Maintains Outperform Rating - marketscreener.com
Martin Shkreli's Biotech Short Position Is Blowing Up As Stock Soars 440%: Momentum Score Spikes - Sahm
Best Biotech Stocks To ConsiderDecember 7th - MarketBeat
Capricor Therapeutics launches proposed public offering of common stock - MSN
Capricor: Maintaining 'Hold' Rating On Randomized Phase 3 HOPE-3 Trial Win With Deramiocel - Seeking Alpha
Capricor stock soars after pivotal DMD cell therapy trial meets endpoints - MSN
Capricor Therapeutics prices $150M stock offering - MSN
Capricor Therapeutics (NASDAQ:CAPR) Shares Gap UpShould You Buy? - MarketBeat
Capricor Therapeutics (CAPR): Assessing Valuation After a Strong Multi-Week Share Price Rally - Sahm
How Recent Developments Are Rewriting the Story for Capricor Therapeutics - Yahoo Finance
Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Phase III Top Line Data for Deramiocel in Duchenne Muscular DystrophySlideshow (NASDAQ:CAPR) 2025-12-05 - Seeking Alpha
Capricor Therapeutics Announces $150 Million Public Offering - TradingView — Track All Markets
CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know - The Globe and Mail
Capricor Therapeutics (CAPR) Stock :Prices $150M Offering for Next-Gen DMD Treatment Development - parameter.io
Capricor Therapeutics (NASDAQ:CAPR) Shares Gap DownShould You Sell? - MarketBeat
Capricor Therapeutics sets pricing of $150 mln public offering of shares - marketscreener.com
Published on: 2025-12-05 06:37:44 - Newser
Capricor Therapeutics (CAPR) Surges After Pricing $150M Stock Of - GuruFocus
CAPR Collaborates with Managers for Successful Offering - GuruFocus
Can Capricor Therapeutics Inc. stock continue upward trendWeekly Profit Report & Consistent Return Strategy Ideas - Newser
Capricor Therapeutics Prices $150 Million Common Stock Offering; Shares Up Pre-Bell - marketscreener.com
Capricor Therapeutics prices public offering at $25 per share - Investing.com
Capricor Therapeutics prices public offering at $25 per share By Investing.com - Investing.com UK
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock - marketscreener.com
Capricor Therapeutics (NASDAQ: CAPR) prices 6M-share offering at $25, targeting $150M - Stock Titan
Why Capricor Therapeutics Inc. (4LN2) stock stays undervaluedMarket Rally & Weekly Stock Performance Updates - Newser
Is Capricor Therapeutics Still Attractive After Its 375% Surge in 2025? - simplywall.st
Geode Capital Management LLC Acquires 61,701 Shares of Capricor Therapeutics, Inc. $CAPR - MarketBeat
Why Capricor Therapeutics Inc. stock remains a top recommendationWeekly Trend Summary & Verified Momentum Stock Ideas - Newser
What insider trading reveals about Capricor Therapeutics Inc. stockJuly 2025 Weekly Recap & Stock Portfolio Risk Control - Newser
Inside Biotech: Capricor’s Duchenne results ignite a 500% surge — and an immediate equity raise - Proactive financial news
Capricor Therapeutics launches common stock offering By Investing.com - Investing.com South Africa
Maxim Group Maintains Capricor Therapeutics (CAPR) Buy Recommendation - Nasdaq
CAPR Stock Update: Piper Sandler and Oppenheimer Lead Offering - GuruFocus
Small Cap Stocks To ResearchDecember 3rd - MarketBeat
Capricor Therapeutics (CAPR) Launches Public Offering Amid Marke - GuruFocus
Capricor Therapeutics announces common stock offering, no amount given - TipRanks
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):